首页 | 本学科首页   官方微博 | 高级检索  
检索        

胸腺肽在糖尿病合并肺结核患者中的应用
引用本文:刘建春,杜敬华,王晓军,王爱民.胸腺肽在糖尿病合并肺结核患者中的应用[J].临床肺科杂志,2014(10):1838-1841.
作者姓名:刘建春  杜敬华  王晓军  王爱民
作者单位:唐山市第四医院, 河北 唐山,063000
摘    要:目的观察并探讨胸腺肽在糖尿病合并结核病患者抗结核治疗中的作用。方法将入选的90例糖尿病合并肺结核患者随机分为观察组(n=47例)和对照组(n=43例),对照组在维持血糖基础上予常规抗结核治疗,观察组在此基础上加用胸腺肽注射液皮下注射,连用12周,对比两组治疗3个月后抗结核治疗效果。结果 1治疗90 d后,观察组CD+4构成比及CD+4/CD+8比值明显高于对照组水平这P0.05,而CD+8构成比(23.3±5.7)%显著低于对照组。2两组血糖控制平稳,观察组与治疗组空洞闭合比例、病灶吸收比例及痰菌阴转比例差异均具有统计学意义。3两组药物不良反应类型与发生率差异无统计学意义。结论糖尿病合并肺结核患者在有效控制血糖基础上,抗结核治疗中加用胸腺肽注射液能提高细胞免疫水平,加快空洞闭合、痰菌阴转与病灶吸收。

关 键 词:2型糖尿病  肺结核  胸腺肽  T淋巴细胞  免疫调节

Application of thymopeptide in the anti-pulmonary tuberculosis treatment of patients complicated with type 2 ;diabetes mellitus
LIU Jian-chun,DU Jing-hua,WANG Xiao-jun,WANG Ai-min.Application of thymopeptide in the anti-pulmonary tuberculosis treatment of patients complicated with type 2 ;diabetes mellitus[J].Journal of Clinical Pulmonary Medicine,2014(10):1838-1841.
Authors:LIU Jian-chun  DU Jing-hua  WANG Xiao-jun  WANG Ai-min
Institution:(the Fourth Hospital of Tangshan , Tangshan , Hebei 063000, China)
Abstract:Objective To observe the clinical efficacy of thymopeptide in the anti-pulmonary tuberculosis treatment of patients complicated with type 2 diabetes mellitus. Methods 90 pulmonary tuberculosis patients complicated with type 2 diabetes mellitus were randomly divided into the observation group( n = 47 cases) and the control group( n = 43 cases). Based on glucose maintenance the control group was given conventional anti-tuberculosis treatment,while the observation group was added with thymopeptide injection subcutaneously. 12 weeks were a treatment course. Results 1 90 days after the treatment,the constituent ratio of CD4^+and the ratio of CD4^+/CD8^+were significantly higher in the observation group than in the control group( t = 3. 456,P = 0. 001; t = 4. 708,P = 0. 000),and CD8^+( 23.3 ± 5.7) % was significantly lower than that in the control group( 28.6 ± 7.4) %( t = 3.781,P =0. 000). 2Blood sugar of the two groups maintained well,but there were significant differences in cavity closure proportion( 50% vs. 22. 7%),focus absorption ratio( 55. 3% vs. 32. 6%) and sputum negative conversion rate( 46.8% vs. 25.6%) between the two groups( fisher P =0.045; 2 =4.712 P =0.030 2 =4.357 P =0.037). 3The incidence of adverse reactions had no significant difference between the two groups( χ2= 0. 045,P = 0. 833).Conclusion On the effective control of blood glucose basis for pulmonary tuberculosis patients with diabetes mellitus,anti-tuberculosis treatment applied with thymopeptide injection can enhance cellular immunity level,accelerate cavity closure,sputum negative conversion and focus absorption. anti with enteric.
Keywords:type 2 diabetes mellitus  pulmonary tuberculosis  thymopeptide  T lymphocytes  immunoregu-lation
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号